title: A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients.
abstract: OBJECTIVE
  This is a randomized, placebo-controlled study of the weight-loss efficacy and safety of a controlled-release (CR) formulation of topiramate in overweight and obese patients with type 2 diabetes treated with diet and exercise alone or in combination with metformin.
  
  
  METHODS
  Patients with type 2 diabetes, BMI > or =27 kg/m2, A1C >6.5 and <11.0%, treated with diet and exercise alone or in combination with metformin monotherapy were enrolled. Patients were randomized to placebo or topiramate CR titrated up to 175 mg/day. Treatment consisted of a 7-week titration phase followed by a 9-week maintenance phase.
  
  
  RESULTS
  A total of 111 subjects were randomized and analyzed. By the end of week 16, patients in the placebo and topiramate groups lost 2.5 and 6.0 kg, which represented 2.3 and 5.8%, respectively, of their baseline body weight (P < 0.001 vs. placebo). A1C improved from a baseline of 7.4% in the placebo and 7.6% in the topiramate groups to 7.1 and 6.7%, respectively, representing a 0.4 and 0.9% reduction from baseline, respectively (P < 0.001 vs. placebo). Topiramate also significantly reduced blood pressure and urinary albumin excretion. Adverse events were predominantly neuropsychiatric or central and peripheral nervous system related.
  
  
  CONCLUSIONS
  Topiramate CR treatment produced significant weight loss and meaningful improvements in A1C and blood pressure in obese patients with type 2 diabetes treated with diet and exercise or in combination with metformin. However, the central nervous system and psychiatric adverse event profile of topiramate CR makes it unsuitable for the treatment of obesity and diabetes.
authors.affiliation: Dallas Diabetes and Endocrine Center, Dallas, Texas 75230, USA. juliorosenstock@dallasdiabetes.com
authors.forename: Julio
authors.initials: J
authors.lastname: Rosenstock
authors.forename: Priscilla
authors.initials: P
authors.lastname: Hollander
authors.forename: Kishore M
authors.initials: KM
authors.lastname: Gadde
authors.forename: Xiang
authors.initials: X
authors.lastname: Sun
authors.forename: Richard
authors.initials: R
authors.lastname: Strauss
authors.forename: Albert
authors.initials: A
authors.lastname: Leung
mesh_terms: D000328:Adult; D000368:Aged; D019440:Anti-Obesity Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D004038:Diet, Reducing; D004311:Double-Blind Method; D015444:Exercise; D005260:Female; D005632:Fructose / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D008297:Male; D008687:Metformin / Q000627:therapeutic use; D008875:Middle Aged; D009765:Obesity / Q000150:complications* / Q000188:drug therapy*; D010919:Placebos; D012449:Safety; D000077236:Topiramate
chemical_list: D019440:Anti-Obesity Agents; D003692:Delayed-Action Preparations; D007004:Hypoglycemic Agents; D010919:Placebos; D000077236:Topiramate; D005632:Fructose; D008687:Metformin